Skip to main content
Fig. 6 | BMC Pharmacology and Toxicology

Fig. 6

From: A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy

Fig. 6

a. Representative organ images showing specific tumor targeting of rhodamine B isothiocyanate labeled TPGS-FA/NC nanoparticles 8 h post-injection into mice bearing Huh7 xenograft (T: tumor, Li: liver, H: heart, L: lung, K:kidney, S: spleen, and B:brain; Color scale: radiant efficiency, [p s− 1 cm− 2 sr− 1] [μWcm− 2]− 1). V b. Quantitative analysis of biodistribution in tumors and normal organs, quantified from the organ images. Intravenous treatment of nude mice bearing orthotopic Huh7 xenografts with TPGS-FA/NC nanoparticles (red) and control groups (turquoise: NC, fuchsia:5-Fu, blue: PBS) every other day for a total of five injections (4 mg kg − 1,NC per body weight, indicated by arrows). c. Mice body weight was monitored during the time course of treatments (n = 5 biologically independent animals, statistics was calculated by two-tailed unpaired t-test presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, p = 4.3 × 10− 3,3.4 × 10− 3 and 5.0 × 10− 4 comparing TPGS-FA/NC to NC,5-Fu and PBS, respectively). d. Representative images of liver cancer tumors harvested from mice after treatments *p < 0.05, **p < 0.01, ***p < 0.001; p = 0.01, 8 × 10 − 4,and 2 × 10 − 4 comparing TPGS-FA/NC to NC, 5-Fu, and PBS, respectively. Source data are provided as a Source Data file

Back to article page